Davis Polk advised
the representatives of the underwriters in connection with the offering of $5.0 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were offered in four tranches, maturing in 2024, 2029, 2039 and 2049.
Merck is a global healthcare leader that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
The Davis Polk capital markets team included partner Byron B. Rooney
and associate Heita Miki. The tax team included partner Lucy W. Farr and associate Ben Levenback. All members of the Davis Polk team are based in the New York office.